"Living a normal life": a qualitative study of patients' views of medication withdrawal in rheumatoid arthritis

Kenneth F Baker, John D Isaacs, Ben Thompson, Kenneth F Baker, John D Isaacs, Ben Thompson

Abstract

Background: Withdrawal of disease-modifying anti-rheumatic drugs (DMARDs) once disease remission is achieved is endorsed by current international rheumatoid arthritis (RA) management guidelines. However, very little data exists concerning patients' views of this practice. In this qualitative study, we aimed to explore patients' perspectives on DMARD withdrawal in the setting of established RA.

Methods: In this qualitative interview study, patients with stable established RA were recruited from rheumatology outpatient clinics at a large UK teaching hospital. The perceived advantages and disadvantages of DMARDs and views on DMARD withdrawal were explored in semi-structured interviews. Interview transcripts were analysed using standard qualitative techniques to construct an analytical framework.

Results: Thirteen participants (8 female, median [IQR] age 65 [61-73]) expressed their views of DMARD treatment in the context of their "normal lives". For some patients, disadvantages such as medication side-effects and the inconvenience of safety monitoring were sufficient hindrances to their lifestyle to justify DMARD withdrawal. However, patients who were vulnerable to loss of physical function, or who had prior experience of severe rheumatoid arthritis, expressed a strong preference against DMARD withdrawal, viewing the potential for increased pain and future disability as unacceptable risks.

Conclusions: Patients view DMARD withdrawal in the context of either restoring or threatening their "normal lives". In this model, social and personal factors play a crucial role in influencing patients' opinions of DMARD therapy beyond a simple consideration of medication side-effects alone. A formulaic approach to DMARD withdrawal determined and imposed by clinicians would not be successful. Instead, the discussion of DMARD withdrawal should take place with the identification of patients' priorities and in the context of their personal disease experiences.

Trial registration: clinicaltrials.gov (NCT02064400), retrospectively registered 17 February 2014.

Keywords: Cessation; DMARD; Qualitative; Remission; Rheumatoid arthritis; Withdraw.

Conflict of interest statement

Competing interestsKFB and JDI are named as inventors on a patent application by Newcastle University relating to the prediction of drug-free remission in rheumatoid arthritis. BT has no competing interests to declare.

References

    1. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637. doi: 10.1136/ard.2009.123919.
    1. Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008;47(6):924–925. doi: 10.1093/rheumatology/kel216a.
    1. Marshall NJ, Wilson G, Lapworth K, Kay LJ. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. Rheumatology (Oxford) 2004;43(8):1034–1038. doi: 10.1093/rheumatology/keh237.
    1. Goodacre LJ, Goodacre JA. Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease-modifying medication. Rheumatology (Oxford) 2004;43(5):583–586. doi: 10.1093/rheumatology/keh116.
    1. Lempp H, Hofmann D, Hatch SL, Scott DL. Patients' views about treatment with combination therapy for rheumatoid arthritis: a comparative qualitative study. BMC Musculoskelet Disord. 2012;13:200. doi: 10.1186/1471-2474-13-200.
    1. Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, et al. Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic disease. J Rheumatol. 2005;32(5):913–919.
    1. Strauss AL, Glaser BG. Chronic illness and the quality of life. 1. St. Louis: Mosby; 1975.
    1. Morse JM, Wilson S, Penrod J. Mothers and their disabled children: refining the concept of normalization. Health Care for Women International. 2000;21(8):659–676. doi: 10.1080/073993300300340501.
    1. van der Woude D, Young A, Jayakumar K, et al. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum. 2009;60(8):2262–2271. doi: 10.1002/art.24661.
    1. Klarenbeek NB, van der Kooij SM, Guler-Yuksel M, et al. Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis. 2011;70(2):315–319. doi: 10.1136/ard.2010.136556.
    1. Haschka J, Englbrecht M, Hueber AJ, et al. Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study. Ann Rheum Dis. 2016;75(1):45–51. doi: 10.1136/annrheumdis-2014-206439.
    1. O’Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2010;69(10):1823–1826. doi: 10.1136/ard.2008.105577.
    1. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi: 10.1136/annrheumdis-2013-204573.
    1. Singh JA, Saag KG, Bridges SL, Jr, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1–26. doi: 10.1002/art.39480.
    1. Scott IC, Kingsley GH, Scott DL. Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis? Clin Exp Rheumatol. 2013;31(4 Suppl 78):S4–S8.
    1. Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions. Ann Rheum Dis. 2016;75(8):1428–1437. doi: 10.1136/annrheumdis-2016-209201.
    1. Barbour RS. Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? Br Med J. 2001;322(7294):1115–1117. doi: 10.1136/bmj.322.7294.1115.
    1. Saunders B, Sim J, Kingstone T, et al. Saturation in qualitative research: exploring its conceptualization and operationalization. Qual Quant. 2018;52(4):1893–1907. doi: 10.1007/s11135-017-0574-8.
    1. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–48. doi: 10.1002/art.1780380107.
    1. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581. doi: 10.1002/art.27584.
    1. Silverman D. Naturally Ocurring talk. In. Interpreting Qualitative Data Methods for Analyzing Talk, Text and Interaction. 3. London: Sage Publications Ltd; 2006. pp. 201–240.
    1. Hsieh H-F, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277–1288. doi: 10.1177/1049732305276687.
    1. Tong A, Craig J, Sainsbury P. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–357. doi: 10.1093/intqhc/mzm042.
    1. The World Medical Association World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi: 10.1001/jama.2013.281053.
    1. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res (Hoboken) 2010;62(5):640–646. doi: 10.1002/acr.20034.
    1. van Tuyl LH, Hewlett S, Sadlonova M, et al. The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'. Ann Rheum Dis. 2015;74(6):1004–1010. doi: 10.1136/annrheumdis-2013-204798.
    1. Fraenkel L, Seng EK, Cunningham M, Mattocks K. Understanding how patients (vs physicians) approach the decision to escalate treatment: a proposed conceptual model. Rheumatology (Oxford) 2015;54(2):278–285. doi: 10.1093/rheumatology/keu324.
    1. Markusse IM, Akdemir G, Huizinga TW, Allaart CF. Drug-free holiday in patients with rheumatoid arthritis: a qualitative study to explore patients' opinion. Clin Rheumatol. 2014;33(8):1155–1159. doi: 10.1007/s10067-014-2500-y.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe